To include your compound in the COVID-19 Resource Center, submit it here.

Humira adalimumab: Additional Phase III data

Additional data from the double-blind, international Phase III ABILITY-1 trial in 179 patients with active non-radiographic axial spondyloarthritis showed that Humira significantly improved Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) scores at week 12 vs. placebo (reductions of 0.3 vs. 0.1

Read the full 409 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE